Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Secondary Hyperlipidemias

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  2016-05-16

• Fields of study

  Medicine, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Amendment history : Correction ( May 1961 ) EFFECTS OF INFUSIONS OF SERUM ALBUMIN ON SERUM LIPIDS AND LIPOPROTEINS IN NEPHROSIS

  2018cited by this paper
• HEAT PRODUCTION IN THE BROWN ADIPOSE TISSUE BY CGRP INJECTION INTO THE VENTROMEDIAL HYPOTHALAMIC NUCLEUS AKIKO

  2018cited by this paper
• Low-Density Lipoprotein Density and Atherosclerosis

  2017cited by this paper
• HDL abnormalities in nephrotic syndrome and chronic kidney disease

  2016cited by this paper
• Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.

  2016cited by this paper
• Pharmacology of cholesterol and lipoprotein metabolism

  2016cited by this paper
• New developments in proprotein convertase subtilisin–kexin 9's biology and clinical implications

  2016cited by this paper
• Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids

  2016cited by this paper
• Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other*

  2015cited by this paper
• Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• Identification of miR-148a as a novel regulator of cholesterol metabolism

  2015cited by this paper
• Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure

  2015cited by this paper
• Leptin in congenital and HIV-associated lipodystrophy.

  2015cited by this paper
• Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis

  2015cited by this paper
• Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.

  2015cited by this paper
• Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol

  2015cited by this paper
• PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice[S]

  2015cited by this paper
• Physiology of leptin: energy homeostasis, neuroendocrine function and metabolism.

  2015cited by this paper
• Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities.

  2015cited by this paper
• Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice[S]

  2015cited by this paper
• Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.

  2015cited by this paper
• PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver

  2015cited by this paper
• Congenital generalized lipodystrophies—new insights into metabolic dysfunction

  2015cited by this paper
• β‐Estradiol results in a proprotein convertase subtilisin/kexin type 9‐dependent increase in low‐density lipoprotein receptor levels in human hepatic HuH7 cells

  2015cited by this paper
• Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.

  2014cited by this paper
• Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.

  2014cited by this paper
• Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides.

  2014cited by this paper
• Congenital Lipodystrophies and Dyslipidemias

  2014cited by this paper
• Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.

  2014cited by this paper
• What we talk about when we talk about fat.

  2014cited by this paper
• Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.

  2014cited by this paper
• PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension.

  2014cited by this paper
• Elevated Circulating PCSK-9 Concentration in Renal Failure Patients is Corrected by Renal Replacement Therapy

  2014cited by this paper
• Effects of Leptin Replacement Therapy on Pancreatic β-Cell Function in Patients With Lipodystrophy

  2014cited by this paper
• Small-molecule SMAC mimetics as new cancer therapeutics.

  2014cited by this paper
• The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression

  2014influential reference
• The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion.

  2014cited by this paper
• Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation

  2013cited by this paper
• Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

  2013cited by this paper
• A mutation in the c-Fos gene associated with congenital generalized lipodystrophy

  2013cited by this paper
• SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion

  2013cited by this paper
• Lipid-lowering agents for nephrotic syndrome.

  2013cited by this paper
• Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.

  2013cited by this paper
• Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome

  2013cited by this paper
• Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis

  2013cited by this paper
• Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation

  2013cited by this paper
• Adiponectin promotes functional recovery after podocyte ablation.

  2013cited by this paper
• Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

  2012cited by this paper
• Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation

  2012cited by this paper
• c-IAP1 Binds and Processes PCSK9 Protein: Linking the c-IAP1 in a TNF-α Pathway to PCSK9-Mediated LDLR Degradation Pathway

  2012cited by this paper
• Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR

  2012cited by this paper
• Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women

  2012cited by this paper
• Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels

  2012cited by this paper
• The PCSK9 decade

  2012cited by this paper
• Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multi-disciplinary approach

  2012cited by this paper
• Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice.

  2012cited by this paper
• Angiotensin II induces tumor necrosis factor-α expression and release from cultured human podocytes

  2012cited by this paper
• Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.

  2012cited by this paper
• Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)*

  2012cited by this paper
• Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.

  2012cited by this paper
• Peroxisome Proliferator-activated Receptor γ Activation by Ligands and Dephosphorylation Induces Proprotein Convertase Subtilisin Kexin Type 9 and Low Density Lipoprotein Receptor Expression*

  2012cited by this paper
• Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor.

  2011cited by this paper
• Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia.

  2011cited by this paper
• Leptin increases skeletal muscle lipoprotein lipase and postprandial lipid metabolism in mice.

  2011cited by this paper
• Lipodystrophies: Genetic and Acquired Body Fat Disorders

  2011cited by this paper
• Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.

  2011cited by this paper
• The proprotein convertases, 20 years later.

  2011cited by this paper
• Nephrotic Syndrome in Children: From Bench to Treatment

  2011cited by this paper
• Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

  2011cited by this paper
• Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

  2011cited by this paper
• Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

  2010cited by this paper
• Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.

  2010cited by this paper
• PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

  2010cited by this paper
• In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9*

  2010cited by this paper
• Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine*

  2009cited by this paper
• LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor

  2009cited by this paper
• Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.

  2009cited by this paper
• Functional Specificities of Brm and Brg-1 Swi/Snf ATPases in the Feedback Regulation of Hepatic Bile Acid Biosynthesis

  2009cited by this paper
• Inducible rodent models of acquired podocyte diseases.

  2009cited by this paper
• Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants*

  2009cited by this paper
• Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice

  2009cited by this paper
• Efficacy of leptin therapy in the different forms of human lipodystrophy

  2009cited by this paper
• The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis

  2009cited by this paper
• Genetic and metabolic determinants of plasma PCSK9 levels.

  2009cited by this paper
• Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

  2009cited by this paper
• Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors.

  2009cited by this paper
• PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

  2009cited by this paper
• Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.

  2008cited by this paper
• The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2*

  2008cited by this paper
• PCSK9 is required for the disposal of non‐acetylated intermediates of the nascent membrane protein BACE1

  2008cited by this paper
• PCSK9 and LDL cholesterol: unravelling the target to design the bullet.

  2008cited by this paper
• Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy.

  2008cited by this paper
• Self-association of human PCSK9 correlates with its LDLR-degrading activity.

  2008cited by this paper
• Cross-talk between estrogen and leptin signaling in the hypothalamus.

  2008cited by this paper
• Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels*

  2008cited by this paper
• Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte‐specific low‐density lipoprotein receptor degradation and critical role in mouse liver regeneration

  2008cited by this paper
• Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2s⃞s⃞ The online version of this article (available at http://www.jlr.org) contains supplementary data. Published, JLR Papers in Press, November 21, 2007.

  2008cited by this paper
• Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9*

  2008cited by this paper
• Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment

  2008cited by this paper

• No citing papers are available for this paper.